ERBB2 and inflammatory breast carcinoma: Prospective trials with neoadjuvant anti-HER2 including patients with IBC have been performed demonstrating improved pCR rates with the addition of pertuzumab to NACT-trastuzumab (44, 45), and improved outcomes with continuation of anti-HER2 treatment in the adjuvant setting (46); however, there was no formal reporting on the results specifically for the IBC cohort.